DAILYPEPTIDE GUIDE
Clinical Pipeline

Maridebart cafraglutide

MariTide · AMG 133

Maridebart cafraglutide is a clinical-stage asset. Trial status and sponsor-reported findings remain time-sensitive and indication-specific.

Compare
EvidenceTier 2
RegulatoryInvestigational
SafetyKnown but Manageable Risks
Clinical phasePhase 3
01

Overview

ClassAntibody–peptide conjugate
Sponsor / developerAmgen
Review statusReviewed
Record IDPEP-022
02

Plain-language guide

What it was designed or studied for

Designed for research into Obesity, Type 2 diabetes, Cardiovascular outcomes. It remains investigational for these uses.

How it works, simply

It copies two gut-hormone signals that help the body respond to food, regulate blood sugar and communicate fullness to the brain.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Combines GIP-receptor antagonism with GLP-1-receptor agonism.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Obesity
  • Type 2 diabetes
  • Cardiovascular outcomes
05

Human evidence

Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.

Tier 2
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

06

Regulatory status

Investigational. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Known but Manageable Risks

  • Adverse effects vary by product and indication
  • Contraindications and interactions require label review
08

Interactions

Review the current product label and indication-specific literature for pharmacologic and absorption interactions.

09

Treatment pattern

Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.

10

Manufacturing and quality

Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • Long-term outcomes and real-world safety are not yet established.
  • Current phase and catalysts require primary-source confirmation.
14

Last reviewed

August 5, 2026 · Reviewed